Name

Wockhardt

Legal name

Wockhardt Limited

Website

https://wockhardt.com

Company type

Public

Founded year

1967

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Novel antibiotic development
• Pharmaceutical manufacturing
• Biosimilar insulin products
• Active pharmaceutical ingredients
• Branded generic medicines

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Branded Generics - India & Emerging Markets: Wockhardt generates significant revenue from its portfolio of branded generic pharmaceuticals sold across India and emerging markets. The company has a strong presence in anti-infectives, with established brands in the Indian pharmaceutical market. Revenue is generated through a network of distributors and field sales representatives targeting hospitals and retail pharmacies.
2. Biosimilars: Wockhardt has developed and commercializes biosimilar products, including a recent launch of a biosimilar pegfilgrastim (Pegficel) in India. These biologic products provide an alternative to expensive originator biologics and generate revenue through hospital and retail pharmacy channels.
3. Novel Antibiotics - Zaynich (US & Global Markets): Following FDA approval, Wockhardt is commercializing Zaynich directly in the US market through its own sales force targeting hospital systems. This represents a shift from traditional generic pricing to branded pharmaceutical pricing with premium positioning justified by clinical differentiation and addressing unmet medical needs in antimicrobial resistance.
4. Contract Manufacturing: Wockhardt operates contract manufacturing services leveraging its USFDA and EMA-approved manufacturing facilities. The company manufactures active pharmaceutical ingredients (APIs) and finished dosage forms for global pharmaceutical companies, providing a steady revenue stream with typically lower margins than branded products.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Wockhardt discovers, develops, manufactures, and commercializes pharmaceutical products with a primary focus on novel antibiotics targeting drug-resistant bacterial infections. Its commercial portfolio includes ZAYNICH, EMROK, EMROK O, and Miqnaf/Nafithromycin, alongside biosimilars (Glaritus, Wosulin, Wepox), active pharmaceutical ingredients (APIs), contract manufacturing services for global pharma companies, and a broad branded generics portfolio sold across India and emerging markets.

Product overview

Wockhardt is a research-based pharmaceutical company operating as an integrated enterprise with 'Concept to Commercialisation' capabilities. The company's product portfolio centers on novel antibiotic discovery, with key products including ZAYNICH (a novel IV antibiotic for resistant Gram-negative infections), EMROK/EMROK O (novel antibiotics for MRSA and Gram-positive infections), Nafithromycin/Miqnaf (respiratory antibiotics), and WCK 4282/WCK 6777 (pipeline antibiotics targeting multi-drug resistant pathogens). The biologics division offers insulin products including Glaritus (biosimilar insulin glargine), Wosulin (human insulin), and Wepox (erythropoietin). Additional business segments include Active Pharmaceutical Ingredients (one of the largest Dextromethorphan HBr manufacturers globally), contract manufacturing services across 15 facilities, and quality generic pharmaceuticals. The company holds 45 patents in biosimilar development and 16 patents for insulin pen technology.

Differentiator

Problem solved

Functional benefit

Brands

• ZAYNICH (Zidebactam/Cefepime): Novel antibiotic for complicated urinary tract infections, first NCE fully developed by an Indian pharma company to receive US FDA approval
• EMROK / EMROK O
• Miqnaf (Nafithromycin)
• Glaritus
• Wosulin
• Wepox

Products and services

• ZAYNICH (Zidebactam/Cefepime - WCK 5222) Novel intravenous antibiotic combining Zidebactam with Cefepime, targeting multi-drug resistant Gram-negative bacteria causing complicated urinary tract infections including pyelonephritis. Designed for hospitalized patients with carbapenem-resistant infections; offered to US hospitals at $10,000-$12,000 per treatment course and at 75-80% lower pricing in India.
• EMROK (Levonadifloxacin - WCK 771) First-in-class antibiotic derived from the benzoquinolizine structural sub-class, approved for acute bacterial skin and skin structure infections including diabetic-foot infections and concurrent bacteraemia caused by Gram-positive pathogens including MRSA. Designated QIDP by US FDA.
• EMROK O (Alalevonadifloxacin - WCK 2349) Oral antibiotic prodrug of levonadifloxacin with approximately 90% oral bioavailability, designed for MDR Gram-positive MRSA infections. No dose adjustments required for renal or hepatic impairment. Designated QIDP by US FDA.
• Miqnaf (Nafithromycin - WCK 4873) Novel oral respiratory antibiotic with an ultra-short-course dosing regimen (800mg once-daily for 3 days) for treatment of community-acquired bacterial pneumonia. Highly potent against respiratory pathogens regardless of azithromycin, penicillin, or quinolone resistance. Designated QIDP by US FDA.
• WCK 4282 (Cefepime/Tazobactam) Globally patented, pharmacodynamically optimised high-dose combination of cefepime and tazobactam for ESBL-producing Gram-negative pathogens, designed as a superior replacement for piperacillin/tazobactam in Phase 3 development. Designated QIDP by US FDA.
• WCK 6777 (Ertapenem/Zidebactam) Once-daily IV antibiotic combination designed as outpatient parenteral antimicrobial therapy (OPAT) for multi-drug resistant Gram-negative infections. Phase 1 trials completed in the US with NIAID/NIH; granted Fast Track designation and QIDP status by US FDA.
• Glaritus (Insulin Glargine) Long-acting biosimilar insulin glargine (100IU/ML) for diabetes treatment, available in vials and cartridges with an in-house developed insulin pen. Backed by 16 globally valid patents for the insulin pen valid until 2035.
• Wosulin (Recombinant Human Insulin) Recombinant human insulin (r-DNA origin) for diabetes management, sold primarily in India and emerging markets.
• Wepox (Recombinant Erythropoietin) Recombinant human erythropoietin (r-DNA origin) available in 10 strengths for anemia treatment, marketed globally.
• Active Pharmaceutical Ingredients (APIs) Active pharmaceutical ingredients manufactured for global supply, including position as one of the largest manufacturers of Dextromethorphan HBr API globally. Over 140 ANDAs in the US and over 60 EU CTD format dossiers developed using complex technologies.
• Contract Manufacturing Services Contract manufacturing of APIs and finished dosage forms for global pharmaceutical companies, leveraging 12-15 facilities approved by UK MHRA, ANVISA, Gulf GCC, WHO GMP, and US FDA. Full turnkey services from development to high-volume commercial manufacture, including sterile manufacturing capabilities (notably for vaccines and injectables).
• Quality Generics Portfolio Extensive portfolio of generic pharmaceuticals spanning antibiotics, cardiac medications, analgesics, corticosteroids, proton pump inhibitors, and other therapeutic categories, marketed globally including India, UK, Ireland, Russia-CIS, and emerging markets.

Quantifiable outcome

• First Indian company to receive FDA approval for a novel antibiotic addressing drug-resistant gram-negative infections
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered major, core and minor.

• Serum Institute of IndiamajorStrategic or Co-development Partner · 15 January 2024Strategic manufacturing partnership for vaccine production in the UK, leveraging Wockhardt's fill-finish capabilities and regulatory-approved manufacturing facilities. This partnership enabled rapid deployment of COVID-19 vaccines in the UK market during the pandemic, demonstrating Wockhardt's ability to serve as a trusted manufacturing partner for global health initiatives.
• AstraZeneca/Oxford UniversitymajorStrategic or Co-development PartnerWockhardt manufactured the Oxford-AstraZeneca COVID-19 vaccine (Covishield) for the Indian market, utilizing its fill-finish capabilities and regulatory infrastructure. This partnership involved technology transfer and manufacturing scale-up to produce hundreds of millions of vaccine doses.
• Government of India - BIRACcoreStrategic or Co-development PartnerResearch partnership with BIRAC (Biotechnology Industry Research Assistance Council) for development of novel antibiotics addressing antimicrobial resistance. BIRAC has supported Wockhardt's R&D programs through funding and regulatory facilitation, reflecting the government's commitment to building indigenous pharmaceutical innovation capabilities.
• Dr. Reddy's LaboratoriesminorOthersIntellectual property settlement and licensing agreement related to patent matters. The companies resolved potential patent disputes through negotiation, demonstrating industry practice of managing IP portfolios and avoiding costly litigation.
• Global Regulatory Authorities (FDA, EMA, WHO)coreOthersRegulatory partnerships and collaborations with global health authorities for drug approvals, clinical trial oversight, and post-marketing surveillance. Wockhardt maintains active engagement with FDA, EMA, WHO Prequalification, and various emerging market regulatory authorities to ensure compliance and expedite approvals.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Dr. Reddy's Laboratories: Indian pharma peer with branded generics, biosimilars, and API businesses. Has prior commercial relationship with Wockhardt via IP licensing and overlaps in anti-infectives and biosimilars.
• Shionogi & Co., Ltd. Japanese pharmaceutical company with Fetcroja (cefiderocol), a siderophore cephalosporin approved for complicated gram-negative infections. Closely comparable to Wockhardt as a focused anti-infectives innovator targeting carbapenem-resistant pathogens in hospitals.
• Aurobindo Pharma: Indian generic and specialty pharmaceutical company with significant antibiotics exposure and US commercial footprint. Comparable in manufacturing scale and regulatory complexity.
• Lupin Limited: Indian pharmaceutical company with strong anti-infectives franchise and US specialty/generics presence. Comparable in therapeutic focus and emerging-market commercialization capabilities.
• Cipla Limited: Indian pharmaceutical peer with overlapping anti-infectives portfolio, strong emerging markets distribution, and growing respiratory and biosimilar franchises. Most directly comparable Indian-listed peer by therapeutic mix and geographic footprint.

Emerging players

• Paratek Pharmaceuticals: Specialty anti-infectives company with Nuzyra (omadacycline) approved for CABP and acute bacterial skin infections. Comparable as a smaller commercial-stage antibiotic innovator focused on resistance.
• Melinta Therapeutics: US-focused anti-infectives company with approved antibiotics targeting resistant pathogens including Baxdela and Orbactiv. Comparable as a specialized, hospital-focused antibiotic company competing for similar formulary slots.

Broad incumbents

• Merck & Co. Markets Recarbrio (imipenem/cilastatin/relebactam) for gram-negative infections and operates a broad hospital anti-infectives portfolio. Direct US hospital competitor to ZAYNICH with established formulary access and IDN relationships.
• Pfizer: Sells Zavicefta (ceftazidime/avibactam) and operates a global hospital anti-infectives franchise. Competes with Wockhardt in the same hospital accounts and IDN formulary committees.

Regional players

• Biocon Limited: Indian biosimilars and pharmaceuticals company with overlap in insulin and biologic franchises comparable to Wockhardt's Glaritus/Wosulin/Wepox portfolio. Most relevant peer for the biosimilars business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=tRR8aYvtleY
• LinkedInlinkedin.com/company/wockhardt

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries8 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wockhardt